P21 (P021): An Adamantylated Peptidomimetic Derived from Ciliary Neurotrophic Factor

Research summary. P21 (also written P021) is a small synthetic peptidomimetic derived from the most active region of ciliary neurotrophic factor (CNTF). It consists of a tetrapeptide based on residues 148–151 of CNTF (Asp-Gly-Gly-Leu) modified with an adamantylated glycine intended to enhance proteolytic stability and blood-brain-barrier penetration. P21 has been studied primarily in Alzheimer's-disease-related rodent models and in models of impaired adult hippocampal neurogenesis. It is investigational and has not progressed to substantial late-stage clinical-trial development.

Molecular profile

• Sequence/scaffold: Asp-Gly-Gly-Leu-(adamantyl)-Gly (DGGL-adamantane-G), with the tetrapeptide DGGL derived from the most active region of CNTF
• Class: CNTF-derived adamantylated peptidomimetic (small peptide-like molecule, not a strict peptide)
• Molecular formula: approximately C₃₀H₅₄N₆O₅ (varies by characterisation)
• Molecular weight: ~578 g/mol
• Synonyms: P021, Peptide 021
• Note: P21 should not be confused with the cyclin-dependent kinase inhibitor protein p21 (CDKN1A / WAF1 / CIP1), which is a completely different molecule.

Origin and rationale

CNTF is an endogenous neurotrophic factor with reported activity supporting neuron survival and neurogenesis. A recombinant CNTF therapeutic (axokine) was developed for amyotrophic lateral sclerosis and obesity research; it produced reliable biological activity but was limited by rapid development of neutralising antibodies, narrow therapeutic windows, and dose-limiting effects. P21 was developed by the Iqbal laboratory at the New York State Institute for Basic Research as a small peptidomimetic that captures the neurogenic / neurotrophic activity of CNTF in a much smaller molecule with substantially better pharmacokinetic properties.

The adamantylated glycine is the key engineering feature: the adamantane group is a hydrophobic cage hydrocarbon that confers proteolytic resistance and improves blood-brain-barrier penetration, both well-established medicinal-chemistry strategies for delivering CNS-active small molecules.

Mechanism of action

P21 is interpreted as acting through the CNTF signalling pathway, although the precise mechanism is debated:

• CNTF-related neurotrophic signalling. Research has reported that P21 elevates expression of brain-derived neurotrophic factor (BDNF) and neurotrophin-4 in CNS tissue.
• Adult hippocampal neurogenesis support. P21 administration has been associated with increases in dentate-gyrus neurogenesis in rodent models, consistent with CNTF-pathway engagement.
• Indirect CNTF receptor engagement. Some published mechanistic work suggests that P21 may not bind the CNTF receptor directly but instead acts on regulators of endogenous CNTF availability. The mechanistic picture remains incompletely resolved.

Preclinical research highlights

Alzheimer's-disease rodent models. A consistent line of research from the originating laboratory has reported that P21 administration in transgenic Alzheimer's-disease mouse models reduces amyloid-β plaque burden, reduces tau hyperphosphorylation, and prevents cognitive decline when administration is initiated before substantial pathology develops [1]. These findings have provided much of the rationale for continued P21 research interest.

Adult hippocampal neurogenesis. P21 has been associated with increases in dentate-gyrus neurogenesis and BDNF expression in rodent models, with associated improvements in spatial-learning and memory paradigms.

Tau pathology. Reductions in tau hyperphosphorylation have been reported in tauopathy-relevant cellular and rodent models.

Comparator with cerebrolysin. P21 has been compared with cerebrolysin (a peptide-mixture neuroprotective preparation) in some published rodent work; the two should not be conflated despite both being framed as neurotrophic-pathway research compounds. P21 is a defined small peptidomimetic; cerebrolysin is an undefined porcine-brain-derived peptide mixture.

Limitations of the evidence base

Several caveats are important when reading the P21 literature:

• The supporting literature is concentrated within a single research programme (Iqbal laboratory and collaborators), and independent replication remains modest.
• The mechanistic relationship to CNTF receptor signalling is incompletely resolved.
• No registered late-stage clinical-trial programmes for P21 appear in major Western trial registries at the time of writing.
• The structural overlap between "P21" and the unrelated CDK inhibitor protein p21 (CDKN1A / WAF1 / CIP1) creates literature-search confusion that researchers should be aware of.

Current research status

P21 is an investigational research compound. It is not approved by the FDA for any indication. Research interest is concentrated in CNTF-pathway pharmacology, adult hippocampal neurogenesis, BDNF biology, and Alzheimer's-disease-related rodent models.

For research-supplier contexts, P21 is supplied as a research-grade investigational compound and is not intended for self-administration.

Key takeaways for researchers

• P21 (P021) is an adamantylated peptidomimetic derived from the most active region of ciliary neurotrophic factor (CNTF).
• The adamantylated glycine is intended to confer proteolytic stability and improve blood-brain-barrier penetration over the unmodified peptide sequence.
• Reported preclinical effects include increases in BDNF and neurotrophin-4 expression, support for adult hippocampal neurogenesis, and reductions in amyloid-β and tau pathology in Alzheimer's-disease rodent models.
• The supporting literature is concentrated in a single research programme; independent Western replication is limited.
• "P21" should not be confused with the unrelated cell-cycle inhibitor protein p21 (CDKN1A / WAF1 / CIP1).
• P21 is not an FDA-approved drug.

References

1. Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. 2016;11:50.
2. Bolognin S, Blanchard J, Wang X, et al. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 2014;127(4):529–542.

---

This article is provided for educational and research purposes only. P21 is a research compound. It is not an approved drug or therapeutic agent and is not intended for human consumption, diagnosis, treatment, cure, or prevention of any disease or condition. All work involving this compound should be conducted by qualified personnel within an appropriate research setting and in compliance with applicable institutional and regulatory requirements.